| Quarterly Financials | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
Revenue  | 68 | 92 | 77 | 95 | 75 | 89 | 99 | 84 | 191 | 146 | 128 | 135 | 132 | 205 | 126 | 145 | 145 | 142 | 121 | 159 | 97 | 171 | 146 | 199 | 110 | 178 | 189 | 202 | 141 | 195 |
| Expenses | 57 | 72 | 71 | 98 | 64 | 75 | 86 | 84 | 177 | 115 | 104 | 107 | 113 | 175 | 112 | 137 | 129 | 127 | 109 | 131 | 85 | 150 | 131 | 176 | 97 | 163 | 159 | 166 | 122 | 162 |
| EBITDA | 11 | 19 | 6 | -3 | 11 | 14 | 13 | 0 | 13 | 31 | 24 | 29 | 19 | 30 | 14 | 8 | 16 | 15 | 12 | 28 | 13 | 21 | 14 | 23 | 13 | 16 | 30 | 36 | 19 | 33 |
| Operating Profit % | 15 % | 18 % | 6 % | -8 % | 13 % | 14 % | 11 % | -2 % | 6 % | 8 % | 15 % | 4 % | 13 % | 13 % | 10 % | 4 % | 10 % | 9 % | 7 % | 16 % | 11 % | 11 % | 8 % | 10 % | 10 % | 4 % | 10 % | 15 % | 11 % | 16 % |
| Depreciation | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 7 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 8 | 8 | 9 | 7 | 8 | 8 | 6 | 7 | 6 | 6 | 6 | 5 | 5 | 6 | 6 |
| Interest | 8 | 11 | 10 | 0 | 6 | 5 | 4 | -2 | 3 | 7 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | -6 | -0 | -12 | -12 | -4 | 1 | 0 | -5 | 2 | 15 | 14 | 18 | 10 | 22 | 5 | 0 | 8 | 6 | 5 | 20 | 5 | 14 | 8 | 18 | 7 | 9 | 25 | 31 | 13 | 27 |
| Tax | 0 | -1 | -1 | -0 | 0 | 0 | 1 | 1 | 0 | 2 | 2 | -17 | -2 | -2 | -1 | 0 | 1 | 0 | 1 | 9 | 4 | 4 | 1 | 7 | 6 | 6 | 5 | 10 | 3 | 6 |
| Net Profit | -6 | 0 | -12 | -12 | -4 | 0 | -1 | -5 | 2 | 13 | 12 | 35 | 12 | 23 | 6 | 0 | 7 | 5 | 3 | 11 | 1 | 10 | 7 | 11 | 1 | 4 | 20 | 21 | 10 | 20 |
| EPS in ₹ | -4.70 | 0.34 | -9.50 | -9.29 | -3.30 | 0.34 | -0.78 | -4.38 | 1.60 | 10.55 | 9.44 | 28.45 | 8.86 | 17.32 | 4.22 | 0.17 | 5.16 | 3.99 | 2.46 | 8.27 | 0.88 | 7.44 | 5.13 | 7.86 | 0.92 | 2.63 | 14.66 | 15.71 | 7.18 | 15.06 |
Venus Remedies
Venus Remedies
833.40
+37.55
(4.72%)
Market Cap
₹1,114.00 Cr
PE Ratio
14.95
Volume
73,996.00
Day High - Low
₹835.55 - ₹799.00
52W High-Low
₹799.80 - ₹270.25
Key Fundamentals
Market Cap
1,114.00 Cr
EPS
33.90
PB Ratio
1.77
Book Value
444.61
EBITDA
84.50
Dividend Yield
0.00 %
Industry
Healthcare Sector
Pharmaceuticals ROE Growth %
-
Debt to Equity
0.04
Analyst Rating and Forecast
- By Refinitiv from1 analysts
Actual
Company News
View All News
Venus Remedies received the final anticipated milestone payment of ₹11 crore from Cipla, completing all commercial milestones under their 2019 licensing agreement for an anti-infective drug targeting multidrug-resistant infections in India. The patented product has delivered therapeutic benefits to over one million patients with no serious drug-related adverse events reported, validating Venus Remedies' AMR-focused research capabilities.
Venus Remedies Resolves All Income Tax Disputes, Eliminates ₹33.44 Crore Contingent Liability
10 days ago
10 days agoVenus Remedies has successfully settled all outstanding income tax matters, resulting in the removal of ₹33.44 crore in contingent liabilities from its books. The company has also obtained refunds for protest deposits previously made during the dispute resolution process.
Venus Remedies Limited reported consolidated revenue from operations of Rs 192.75 crores for the quarter ended September 30, 2025, compared to Rs 137.18 crores in the previous quarter, marking significant growth. Net profit for the quarter stood at Rs 20.13 crores versus Rs 9.60 crores in the preceding quarter. For the half-year period, consolidated revenue reached Rs 329.93 crores with net profit of Rs 29.73 crores. However, the company's German subsidiary Venus Pharma GmbH faces financial difficulties with negative net worth of Rs 132.10 lakhs. The subsidiary reported revenue of Rs 10.61 crores and net profit of Rs 1.21 crores for the quarter. Management expects the subsidiary's financial position to improve by the end of financial year 2025-26 through proposed financial support and revival strategies. Share application money of Rs 2,859.72 lakhs remains pending for allotment in the German subsidiary as it's not mandatory under German laws. The company operates primarily in the pharmaceuticals segment.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,807.20 | #1 4,33,607.82 | 40.88 | #1 54,729.00 | 9.71 | #1 10,980 | 2.89 | 61.05 | |
6,430.00 | 1,70,696.30 | 67.22 | 9,712.00 | 18.67 | 2,191 | 35.10 | 49.41 | |
3,799.00 | 1,28,575.42 | 59.98 | 11,539.40 | 6.99 | 1,911 | 30.46 | 60.62 | |
1,512.30 | 1,22,156.65 | 22.14 | 28,409.50 | 7.12 | 5,291 | 3.71 | 47.64 | |
1,273.50 | 1,06,288.06 | #1 18.20 | 33,741.20 | 16.73 | 5,725 | -0.38 | 57.95 | |
2,081.80 | 95,087.16 | 21.59 | 22,909.50 | 13.74 | 3,306 | #1 72.75 | 59.68 | |
922.55 | 92,830.12 | 18.48 | 23,511.00 | 18.55 | 4,615 | 34.60 | 37.29 | |
2,166.80 | 89,436.51 | 49.98 | 12,744.20 | #1 20.90 | 2,007 | -21.05 | 30.56 | |
1,172.20 | 68,081.57 | 19.89 | 32,345.60 | 9.43 | 3,484 | 3.81 | 45.41 | |
5,626.00 | 67,267.27 | 27.77 | 13,458.30 | 3.70 | 2,216 | 10.98 | 48.53 |
Growth Rate
Revenue Growth
9.10 %
Net Income Growth
58.95 %
Cash Flow Change
131.80 %
ROE
38.36 %
ROCE
51.90 %
EBITDA Margin (Avg.)
8.79 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 841 | 843 | 765 | 751 | 733 | 644 | 556 | 580 | 601 | 627 | 716 |
| Fixed Assets | 444 | 453 | 406 | 389 | 364 | 289 | 262 | 241 | 216 | 219 | 229 |
| Current Assets | 233 | 277 | 259 | 260 | 265 | 294 | 234 | 278 | 323 | 360 | 452 |
| Capital Work in Progress | 78 | 80 | 66 | 65 | 65 | 25 | 25 | 25 | 26 | 21 | 26 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 20 | 19 | 84 |
| Other Assets | 319 | 310 | 293 | 297 | 304 | 330 | 269 | 314 | 339 | 368 | 376 |
| Total Liabilities | 841 | 843 | 765 | 751 | 733 | 644 | 556 | 580 | 601 | 627 | 716 |
| Current Liabilities | 163 | 193 | 197 | 230 | 264 | 225 | 97 | 93 | 83 | 79 | 136 |
| Non Current Liabilities | 222 | 212 | 180 | 159 | 137 | 96 | 58 | 47 | 58 | 60 | 19 |
| Total Equity | 457 | 438 | 389 | 362 | 333 | 323 | 400 | 440 | 460 | 488 | 561 |
| Reserve & Surplus | 445 | 426 | 376 | 350 | 320 | 311 | 374 | 427 | 447 | 474 | 548 |
| Share Capital | 11 | 11 | 12 | 12 | 12 | 12 | 12 | 13 | 13 | 13 | 13 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | -1 | 4 | -4 | 0 | -1 | -0 | 27 | 14 | -22 | 28 | 9 |
| Investing Activities | -67 | 3 | -18 | 9 | -11 | -5 | 57 | -17 | -58 | -9 | -77 |
| Operating Activities | 68 | 47 | 59 | 31 | 45 | 78 | 132 | 41 | 37 | 37 | 86 |
| Financing Activities | -1 | -46 | -44 | -39 | -35 | -73 | -162 | -10 | -1 | -1 | -1 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
| Promoter | 35.89 % | 40.81 % | 40.81 % | 40.81 % | 40.81 % | 41.76 % | 41.76 % | 41.76 % | 41.76 % | 41.76 % | 41.76 % | 41.76 % | 41.76 % | 41.76 % | 41.76 % | 41.76 % | 41.76 % | 41.76 % | 41.76 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 1.03 % | 1.59 % | 1.48 % | 1.06 % | 1.18 % | 1.11 % | 1.34 % | 2.24 % | 1.86 % |
| DIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.15 % | 0.15 % | 0.15 % | 0.15 % | 0.15 % | 0.15 % | 0.15 % | 0.15 % | 0.15 % | 0.00 % | 0.00 % | 0.11 % | 0.75 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 54.71 % | 51.21 % | 51.95 % | 52.18 % | 51.72 % | 49.97 % | 50.18 % | 50.04 % | 49.24 % | 48.66 % | 48.20 % | 47.25 % | 46.89 % | 46.25 % | 45.31 % | 45.42 % | 46.81 % | 47.70 % | 45.30 % |
| Others | 9.39 % | 7.98 % | 7.24 % | 7.01 % | 7.48 % | 8.27 % | 7.91 % | 8.05 % | 8.85 % | 9.43 % | 8.86 % | 9.24 % | 9.73 % | 10.78 % | 11.61 % | 11.71 % | 10.09 % | 8.19 % | 10.33 % |
| No of Share Holders | 13,829 | 13,846 | 16,617 | 18,231 | 19,952 | 21,189 | 22,015 | 22,243 | 21,719 | 20,498 | 19,267 | 19,560 | 19,913 | 19,614 | 19,557 | 19,771 | 19,982 | 19,307 | 17,725 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 23 Sept 2024 |  Annual General Meeting | NA | 23 Sept 2024 | 339.15 | 342.30 |
| 29 Oct 2024 |  Quarterly Result Announcement | NA | 29 Oct 2024 | 345.90 | 343.60 |
| 04 Feb 2025 | Quarterly Result Announcement | NA | 04 Feb 2025 | 294.10 | 288.35 |
| 26 May 2025 | Quarterly Result Announcement | NA | 26 May 2025 | 344.05 | 355.60 |
| 01 Aug 2025 | Quarterly Result Announcement | NA | 01 Aug 2025 | 540.15 | 524.40 |
| 22 Aug 2025 | Annual General Meeting | NA | 22 Aug 2025 | 431.95 | 494.60 |
| 10 Nov 2025 | Quarterly Result Announcement | NA | 10 Nov 2025 | 441.00 | 448.85 |
Announcements
Venus Remedies Marks Completion Of AMR Licensing Milestones With Final ?11 Crore Payment3 days ago
3 days agoUpdate On Resolution Of Income Tax Matters And Elimination Of Contingent Liability.10 days ago
10 days agoSocial Media Communication Regarding Special Window For Re-Lodgement Of Transfer Requests Of Physical Shares Of Venus Remedies LimitedNov 28, 2025
Nov 28, 2025Clarification On Movement In VolumeNov 20, 2025
Nov 20, 2025Clarification sought from Venus Remedies LtdNov 20, 2025
Nov 20, 2025Social Media Communication Regarding Special Window For Re-Lodgement Of Transfer Requests Of Physical Shares Of Venus Remedies LimitedNov 17, 2025
Nov 17, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 12, 2025
Nov 12, 2025Unaudited Financial Results As On 30Th September 2025Nov 10, 2025
Nov 10, 2025Board Meeting Outcome for Outcome Of Board Meeting Dated 10Th November 2025Nov 10, 2025
Nov 10, 2025Social Media Communication Regarding Special Window For Re-Lodgement Of Transfer Requests Of Physical Shares.Oct 28, 2025
Oct 28, 2025Board Meeting Intimation for Board Meeting Scheduled To Be Held On 10Th November 2025.Oct 27, 2025
Oct 27, 2025SEBI Circular - Special Window For Re-Lodgement Of Transfer Requests Of Physical Shares - Monthly Report.Oct 18, 2025
Oct 18, 2025Social Media Communication Regarding Special Window For Re-Lodgement Of Transfer Requests Of Physical Shares.Oct 10, 2025
Oct 10, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 09, 2025
Oct 09, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationOct 07, 2025
Oct 07, 2025Closure of Trading WindowSep 22, 2025
Sep 22, 2025Social Media CommunicationSep 20, 2025
Sep 20, 2025Social Media Post On Saksham Niveshak Campaign By IEPF.Sep 11, 2025
Sep 11, 2025Social Media Communication Regarding Special Window For Re-Lodgement Of Transfer Requests Of Physical Shares Of Venus Remedies LimitedAug 27, 2025
Aug 27, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportAug 23, 2025
Aug 23, 2025Special Window For Re-Lodgement Of Transfer Requests Of
Physical Shares - Report For July 2025Aug 23, 2025
Aug 23, 2025Special Window For Re-Lodgement Of Transfer Requests Of Physical Shares - Report For July 2025Aug 23, 2025
Aug 23, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMAug 22, 2025
Aug 22, 2025Social Media Post On Saksham Niveshak CampaignAug 21, 2025
Aug 21, 2025Social Medial Announcement.Aug 14, 2025
Aug 14, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 13, 2025
Aug 13, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 03, 2025
Aug 03, 2025Unaudited Financial Results For The Quarter Ended On 30Th June 2025Aug 01, 2025
Aug 01, 2025Board Meeting Outcome for Outcome Of Board Meeting Dated 1St August 2025.Aug 01, 2025
Aug 01, 2025Social Media Communication Regarding Special Window For Re-Lodgement Of Transfer Requests Of Physical Shares Of Venus Remedies LimitedJul 29, 2025
Jul 29, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 26, 2025
Jul 26, 2025Reg. 34 (1) Annual Report.Jul 24, 2025
Jul 24, 2025Notice Of Annual General Meeting Dated 22Nd August 2025.Jul 24, 2025
Jul 24, 2025Board Meeting Intimation for Notice Of Board Meeting Dated 1St August 2025.Jul 22, 2025
Jul 22, 2025Update On Trading In Shares Of Venus Remedies Ltd.Jul 21, 2025
Jul 21, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 11, 2025
Jul 11, 2025Board Meeting Outcome for Outcome Of Board Meeting Dated 8Th July 2025.Jul 08, 2025
Jul 08, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 08, 2025
Jul 08, 2025Board Meeting Intimation for Notice Of Board Meeting To Be Held On 8Th July 2025Jun 27, 2025
Jun 27, 2025Closure of Trading WindowJun 24, 2025
Jun 24, 2025Closure of Trading WindowJun 24, 2025
Jun 24, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 28, 2025
May 28, 2025Announcement under Regulation 30 (LODR)-Change in ManagementMay 26, 2025
May 26, 2025Audited Financial Results As On 31.03.2025May 26, 2025
May 26, 2025Board Meeting Outcome for Outcome Of Board Meeting Dated 26.05.2025.May 26, 2025
May 26, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 22, 2025
May 22, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 21, 2025
May 21, 2025Board Meeting Intimation for The Meeting Of Board Of Directors Is Scheduled To Be Held On 26Th May 2025.
May 17, 2025
May 17, 2025Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure AApr 22, 2025
Apr 22, 2025Change In Email Address Of RTAApr 18, 2025
Apr 18, 2025Technical Indicators
RSI(14)
Neutral 75.55
ATR(14)
Volatile 42.45
STOCH(9,6)
Neutral 76.99
STOCH RSI(14)
Oversold 12.39
MACD(12,26)
Bullish 1.81
ADX(14)
Very Strong Trend 50.35
UO(9)
Bearish 67.10
ROC(12)
Uptrend And Accelerating 11.01
WillR(14)
Overbought -2.59
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
